vaccine is undoubtedly one of the most milestone inventions in the struggle between humans and diseases. Similarly, in the treatment of cancer, vaccines have also played an important role!
If you compare PD-1/L1 to the first "ace" of immunotherapy, and adoptive cellular immunotherapy to the second "ace", then the third "ace" of immunotherapy is undoubtedly a tumor vaccine! This is also the protagonist of the Cancer Free Home editor today!
Breast cancer GP2 vaccine has achieved 5 years of recurrence-free, ushering in a new dawn of cure
at this year's 2020 Santo Anio Breast Cancer Symposium (SABCS) presented a picture of the results of a 5-year follow-up of breast cancer patients, which suddenly became popular All over the circle of cancer friends. This tumor vaccine , called GP2, caused a great sensation with the momentum of a ride. With a 5-year follow-up of , the recurrence rate of breast cancer was 0% , let us see the dawn of clinical cure for tumor!
The picture is very intuitive. After 5 years of follow-up, 46 HER2+ patients received GP2+GM-CSF (granulocyte-macrophage colony stimulating factor, an FDA-approved immune adjuvant) treatment, 5 years without The disease survival rate (DFS) is 100%, and there is no recurrence! The 5-year DFS rate of 50 placebo patients who received only GM-CSF treatment was 89.4%. The
GP2 vaccine showed good tolerance in the absence of serious adverse events, and a strong immune response was obtained through local skin tests and immune tests. The anti-cancer principle of this new tumor vaccine
:
GP2 contains a 9 amino acid transmembrane peptide derived from the HER2/neu protein. HER2/neu is a cell surface receptor protein, expressed in 75% of breast cancers and other common cancers. And GP2 can train patients' T cells to recognize and destroy HER2/neu-expressing cancer cells and avoid recurrence.
We all know that the first anti-HER2 targeted drug was trastuzumab , and then the targeted therapy of HER2+ breast cancer ushered in more new advances. So far, at least 9 drugs for the treatment of HER2+ breast cancer have been approved worldwide, including trastuzumab, lapatinib, pertuzumab, T-DM1, nelatinib, pirotinib, DS -8201, Tucatinib , and trastuzumab approved in June this year. These drugs have brought clear treatment effects and more treatment options to patients with HER2 breast cancer.
There are currently 2 breast cancer targeted drugs targeting HER2 that are currently recruiting patients. If you want to know detailed admission criteria, please consult the Cancer-Free Homeland Medicine Department.
In addition to the major breakthroughs made by tumor vaccines in the field of breast cancer, in fact, in 2020, the global cancer "therapeutic vaccine" research and development will blossom everywhere, and various cancer vaccines have come out! This undoubtedly represents a blowout era for personalized cancer vaccines!
Head and neck cancer: 90% disease control rate! The dawn of the mRNA-4157 vaccine is emerging. The vaccine first introduced is the new personalized cancer vaccine mRNA-4157, which was screened in the medical circle some time ago. The latest phase 1 clinical trial data is very exciting. The disease control rate is as high as 90% , surpassing many targeted and immunotherapeutic drugs already on the market, and it is worth looking forward to.
This vaccine uses a novel gene-based technology to compare the patient’s normal cell DNA sequence with the tumor’s normal DNA sequence and determine the tumor’s specific changes in DNA. By combining with pembrolizumab (a type of PD-1), the researchers speculate that the vaccine can trigger the immune system,Make it more sensitive to PD-1 inhibitors and reduce the risk of cancer recurrence.
On November 11, 2020, Moderna announced that mRNA-4157 combined with Keytruda can shrink a variety of advanced solid tumors.
Among 10 HPV-negative head and neck squamous cell carcinoma patients, the total remission rate of was 50%: 2 cases of complete remission and 3 cases of partial remission. At the same time, 4 patients had stable disease, and the disease control rate (DCR) of reached 90%. Compared with the PD-1 inhibitor alone,
has obvious advantages: the median progression-free survival (mPFS) is 9.8 months.
The results are satisfactory even when compared with the Keytruda/chemo combination (standard of care for first-line treatment), which produced an overall response rate of 36% and a median progression-free survival of 4.9 months.
The 2-year disease-free survival rate is 73%, and the TLPLDC vaccine has a strong curative effect in the treatment of melanoma .
The next innovative cancer vaccine TLPLDC will be introduced. At the 2020 ASCO-SITC clinical immuno-oncology conference, the subgroup analysis results of the phase IIb clinical trial of the TLPLDC vaccine for the treatment of melanoma were announced.
This trial included a total of 144 patients with stage III (advanced) and stage IV (metastatic) melanoma who had been resected, and the main analysis data has been published before that:
is following the clinical research protocol (PT) population analysis In comparison with the comfort crew, the 24-month disease-free survival rate of the TLPLDC treatment group was significantly improved (62.9% vs 34.8%) , showed that the relative risk of disease recurrence was reduced by nearly 50%.
In the intention-to-treat (ITT) population analysis, the TLPLDC treatment group and the placebo group had no significant improvement in disease-free survival at 24 months (38.5% vs 27%), , but in this analysis, the total 24 months The survival rate (OS) has a stronger improvement trend (86.4% vs 75.1%). The dawn of a new type of dendritic cell vaccine
has appeared, with an overall 15-month survival period of 76%!
On April 8, 2020, the Phase II clinical trial data of the new dendritic cell therapy AV-GBM-1 was announced. Research shows that this new vaccine can prolong the mid-term overall survival of
in newly diagnosed glioblastoma patients. Great potential.
In 50 evaluable patients treated with AV-GBM-1, the overall survival rate of at 15 months was 76% , while the overall survival of 287 patients in the control group who received standard treatment was 12 months and 15 months. The rates are 61% and 48% respectively. This shows that the 15-month overall survival rate of patients treated with AV-GBM-1 has increased by 28% , and the curative effect is exceptionally significant . The total remission rate of
has doubled, and the ilixadencel vaccine is expected to become the first-line treatment. The
ilixadencel vaccine is an allogeneic dendritic cell (DC) vaccine. The latest global phase II MERECA clinical trial data was announced at the 2020 ASCO-SITC clinical immuno-oncology conference that ended not long ago, showing that ilixadencel is combined with the targeted anticancer drug sunitinib (Sutan, common name: sunitinib) first-line treatment of newly diagnosed advanced metastatic renal cell carcinoma (mRCC) patients, and aloneCompared with patients treated with sunitinib, the total remission rate is doubled, the complete remission rate is higher, and the remission is longer!
This study shows that ilixadencel combined with sunitinib in the first-line treatment of advanced renal cancer can greatly improve the effective rate of treatment, the overall survival rate and complete remission rate of patients, and it is safer. This new vaccine has unlimited potential and targets 6 cancer types. includes solid tumors such as kidney cancer, liver cancer, gastrointestinal stromal tumor , head and neck tumors, non-small cell lung cancer and gastric cancer . We look forward to further It is hoped that this vaccine can be marketed as soon as possible to benefit patients.
reduces the risk of death by 62%. The DCVAC/OvCa vaccine brings good news to patients with ovarian cancer
DCVAC dendritic vaccine is a kind of active cell immunotherapy, which uses its own dendritic cells to produce and customize for each patient, trying to induce tumor targeting Immune response to antigen.
At the 50th Annual Meeting of the Society of Gynecological Oncology (SGO) in 2019, the final results of a phase II clinical trial SOV02 were announced: patients with relapsed, platinum-sensitive, epithelial ovarian cancer using dendritic cell-based immunotherapy DCVAC/OvCa Adding to the standard carboplatin and gemcitabine regimen, can extend the overall survival (OS) of patients with advanced recurrence of ovarian cancer by more than one year. and DCVAC/OvCa reduced the risk of death from second-line treatment of ovarian cancer by 62%. The overall survival (OS) increased significantly by 13.4 months. The median progression-free survival rate (mPFS) increased by 1.8 months. The global phase III study will be launched soon. The
dendritic vaccine has been widely recognized internationally!
Currently, most dendritic cell vaccines have been widely recognized in the international medical anti-tumor field and have been used in the clinical treatment of a variety of cancers. This is a new hope for the treatment of cancer patients.
Among them, is the most eye-catching Provenge (sipuleucel T), which is the first vaccine approved for treatment in the United States, creating a new era of cancer immunotherapy.
In addition, Germany and Japan also have dendritic cell vaccines for clinical adjuvant treatment of a variety of cancers, such as lung cancer, liver cancer, kidney cancer, breast cancer, and skin cancer. Patients who want to seek help from new treatment technologies at home and abroad can first submit their medical records to the Cancer-Free Homeland Medical Department for preliminary evaluation.
